Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, intravenous fluids, and active pharmaceutical ingredients in Bangladesh. More Details
Solid track record with excellent balance sheet.
Share Price & News
How has Beximco Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BXP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BXP exceeded the UK Pharmaceuticals industry which returned 0.4% over the past year.
Return vs Market: BXP exceeded the UK Market which returned -16.2% over the past year.
Price Volatility Vs. Market
How volatile is Beximco Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Beximco Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BXP (£0.59) is trading above our estimate of fair value (£0.32)
Significantly Below Fair Value: BXP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BXP is good value based on its PE Ratio (13.7x) compared to the GB Pharmaceuticals industry average (17.4x).
PE vs Market: BXP is good value based on its PE Ratio (13.7x) compared to the UK market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: BXP is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: BXP is good value based on its PB Ratio (1.5x) compared to the GB Pharmaceuticals industry average (4.5x).
How is Beximco Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BXP's forecast earnings growth (14.6% per year) is above the savings rate (1.2%).
Earnings vs Market: BXP's earnings (14.6% per year) are forecast to grow slower than the UK market (24.1% per year).
High Growth Earnings: BXP's earnings are forecast to grow, but not significantly.
Revenue vs Market: BXP's revenue (10.7% per year) is forecast to grow faster than the UK market (6% per year).
High Growth Revenue: BXP's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BXP's Return on Equity is forecast to be low in 3 years time (12.2%).
How has Beximco Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BXP has high quality earnings.
Growing Profit Margin: BXP's current net profit margins (13.7%) are higher than last year (13.1%).
Past Earnings Growth Analysis
Earnings Trend: BXP's earnings have grown by 13.5% per year over the past 5 years.
Accelerating Growth: BXP's earnings growth over the past year (20%) exceeds its 5-year average (13.5% per year).
Earnings vs Industry: BXP earnings growth over the past year (20%) exceeded the Pharmaceuticals industry 9.8%.
Return on Equity
High ROE: BXP's Return on Equity (10.8%) is considered low.
How is Beximco Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BXP's short term assets (BDT13.1B) exceed its short term liabilities (BDT12.3B).
Long Term Liabilities: BXP's short term assets (BDT13.1B) exceed its long term liabilities (BDT5.9B).
Debt to Equity History and Analysis
Debt Level: BXP's debt to equity ratio (35%) is considered satisfactory.
Reducing Debt: BXP's debt to equity ratio has increased from 20.5% to 35% over the past 5 years.
Debt Coverage: BXP's debt is well covered by operating cash flow (38.7%).
Interest Coverage: BXP's interest payments on its debt are well covered by EBIT (5.2x coverage).
What is Beximco Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BXP's dividend (1.3%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.82%).
High Dividend: BXP's dividend (1.3%) is low compared to the top 25% of dividend payers in the UK market (5.3%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, BXP has been paying a dividend for less than 10 years.
Growing Dividend: BXP's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (17.8%), BXP's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BXP's dividends in 3 years are forecast to be well covered by earnings (25.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nazmul Hassan, MP has been the Managing Director at Beximco Pharmaceuticals Limited since May 2009. Mr. Hassan served as the Managing Director of Shinepukur Ceramics Limited until November 14, 2013. Pr ...
|MD & Director||11.42yrs||no data||no data|
|Chief Financial Officer||no data||no data||no data|
|Chief Operating Officer||11.42yrs||no data||no data|
|Executive Director of Accounts & Finance||no data||no data||no data|
|Deputy General Manager of Human Resources||no data||no data||no data|
|Company Secretary & Executive Director||no data||no data||no data|
|Director of International Marketing||10.75yrs||no data||no data|
|Executive Director of Quality Assurance||no data||no data||no data|
|Director of Marketing||no data||no data||no data|
Experienced Management: BXP's management team is seasoned and experienced (11.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Beximco Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Beximco Pharmaceuticals Limited
- Ticker: BXP
- Exchange: AIM
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ৳46.923b
- Listing Market Cap: ৳422.632m
- Shares outstanding: 405.56m
- Website: https://www.beximcopharma.com
Number of Employees
- Beximco Pharmaceuticals Limited
- 19 Dhanmondi R/A
- Road No. 7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BXPHARMA||DSE (Dhaka Stock Exchange Ltd.)||Yes||Ordinary Shares||BD||BDT||Apr 1996|
|BXP||AIM (London Stock Exchange AIM Market)||SPON GDR REP ONE ORD SH OF TAKA 10 REG S||GB||GBP||Oct 2005|
|R2WA||DB (Deutsche Boerse AG)||SPON GDR REP ONE ORD SH OF TAKA 10 REG S||DE||EUR||Oct 2005|
|R2WA||BST (Boerse-Stuttgart)||SPON GDR REP ONE ORD SH OF TAKA 10 REG S||DE||EUR||Oct 2005|
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products, intravenous fluids, and active pharmaceutical ingredients in Bangladesh. The company offers allergic di ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 20:41|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.